Cargando…

Delayed Cutaneous Hypersensitivity Reaction to Vaxzevria (ChAdOx1-S) Vaccine against SARS-CoV-2

Recently, an increasing number of cases with delayed cutaneous reaction after immunization with mRNA-based vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been reported. This adverse reaction, which is considered a delayed-type or T cell-mediated hypersensitivity r...

Descripción completa

Detalles Bibliográficos
Autores principales: Sprute, Rosanne, Schumacher, Sofie, Pauls, Martina, Pauls, Wolfgang, Cornely, Oliver A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8339386/
https://www.ncbi.nlm.nih.gov/pubmed/34351606
http://dx.doi.org/10.1007/s40268-021-00358-z
_version_ 1783733588307476480
author Sprute, Rosanne
Schumacher, Sofie
Pauls, Martina
Pauls, Wolfgang
Cornely, Oliver A.
author_facet Sprute, Rosanne
Schumacher, Sofie
Pauls, Martina
Pauls, Wolfgang
Cornely, Oliver A.
author_sort Sprute, Rosanne
collection PubMed
description Recently, an increasing number of cases with delayed cutaneous reaction after immunization with mRNA-based vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been reported. This adverse reaction, which is considered a delayed-type or T cell-mediated hypersensitivity reaction, has been described for the Moderna (mRNA-1273) and Comirnaty (Pfizer/BioNTech, BNT162b2) vaccines. We describe a delayed large local cutaneous reaction in a patient who received the viral vector vaccine Vaxzevria (ChAdOx1-S, AstraZeneca). The time course and clinical symptoms of delayed skin reaction after mRNA vaccines have a similar pattern that we recognized in our patient after Vaxzevria vaccination. This phenomenon has not been described in the Vaxzevria clinical trials and is to our knowledge the first report of this adverse reaction to a vector-based SARS-CoV-2 vaccine. With this, we hope to raise awareness about delayed injection site reactions that also occur after viral vector vaccines and to encourage additional reporting and patient education regarding the cutaneous reactions after coronavirus disease 2019 (COVID-19) vaccination.
format Online
Article
Text
id pubmed-8339386
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-83393862021-08-06 Delayed Cutaneous Hypersensitivity Reaction to Vaxzevria (ChAdOx1-S) Vaccine against SARS-CoV-2 Sprute, Rosanne Schumacher, Sofie Pauls, Martina Pauls, Wolfgang Cornely, Oliver A. Drugs R D Case Report Recently, an increasing number of cases with delayed cutaneous reaction after immunization with mRNA-based vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been reported. This adverse reaction, which is considered a delayed-type or T cell-mediated hypersensitivity reaction, has been described for the Moderna (mRNA-1273) and Comirnaty (Pfizer/BioNTech, BNT162b2) vaccines. We describe a delayed large local cutaneous reaction in a patient who received the viral vector vaccine Vaxzevria (ChAdOx1-S, AstraZeneca). The time course and clinical symptoms of delayed skin reaction after mRNA vaccines have a similar pattern that we recognized in our patient after Vaxzevria vaccination. This phenomenon has not been described in the Vaxzevria clinical trials and is to our knowledge the first report of this adverse reaction to a vector-based SARS-CoV-2 vaccine. With this, we hope to raise awareness about delayed injection site reactions that also occur after viral vector vaccines and to encourage additional reporting and patient education regarding the cutaneous reactions after coronavirus disease 2019 (COVID-19) vaccination. Springer International Publishing 2021-08-05 2021-12 /pmc/articles/PMC8339386/ /pubmed/34351606 http://dx.doi.org/10.1007/s40268-021-00358-z Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Case Report
Sprute, Rosanne
Schumacher, Sofie
Pauls, Martina
Pauls, Wolfgang
Cornely, Oliver A.
Delayed Cutaneous Hypersensitivity Reaction to Vaxzevria (ChAdOx1-S) Vaccine against SARS-CoV-2
title Delayed Cutaneous Hypersensitivity Reaction to Vaxzevria (ChAdOx1-S) Vaccine against SARS-CoV-2
title_full Delayed Cutaneous Hypersensitivity Reaction to Vaxzevria (ChAdOx1-S) Vaccine against SARS-CoV-2
title_fullStr Delayed Cutaneous Hypersensitivity Reaction to Vaxzevria (ChAdOx1-S) Vaccine against SARS-CoV-2
title_full_unstemmed Delayed Cutaneous Hypersensitivity Reaction to Vaxzevria (ChAdOx1-S) Vaccine against SARS-CoV-2
title_short Delayed Cutaneous Hypersensitivity Reaction to Vaxzevria (ChAdOx1-S) Vaccine against SARS-CoV-2
title_sort delayed cutaneous hypersensitivity reaction to vaxzevria (chadox1-s) vaccine against sars-cov-2
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8339386/
https://www.ncbi.nlm.nih.gov/pubmed/34351606
http://dx.doi.org/10.1007/s40268-021-00358-z
work_keys_str_mv AT spruterosanne delayedcutaneoushypersensitivityreactiontovaxzevriachadox1svaccineagainstsarscov2
AT schumachersofie delayedcutaneoushypersensitivityreactiontovaxzevriachadox1svaccineagainstsarscov2
AT paulsmartina delayedcutaneoushypersensitivityreactiontovaxzevriachadox1svaccineagainstsarscov2
AT paulswolfgang delayedcutaneoushypersensitivityreactiontovaxzevriachadox1svaccineagainstsarscov2
AT cornelyolivera delayedcutaneoushypersensitivityreactiontovaxzevriachadox1svaccineagainstsarscov2